We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
BioArctic AB announced the company has received approval by Fimea and Valvira, as well as the local ethics committee for inclusion of Finnish patients in BioArctic's ongoing clinical Phase 1/2 study with SC0806.